Breast Cancer Research and Treatment This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Characteristics and risk factors of axillary lymph node metastasis of microinvasive breast cancer
ConclusionLow ALNM rate (4.1%) suggests that routine SLNB for patients with MIBC is unnecessary but  can be valuable for patients with specific risk factors. Ongoing trials for omitting SLNB in early breast cancer, and further subanalyses focusing on rare populations with MIBC are necessary. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 25, 2024 Category: Cancer & Oncology Source Type: research

Indocyanine green angiography guidance for vascular preservation in skin and nipple sparing mastectomy
ConclusionThis prospective study using preoperative ICG perfusion mapping demonstrated safety, feasibility, and good prognostic outcomes.Level of evidenceIII. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 25, 2024 Category: Cancer & Oncology Source Type: research

Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey
ConclusionTrials to investigate who can safely and effectively be treated with shorter durations of anti-HER2 therapy are needed. This study provides important insights to patients ’ perspectives on shorter durations of anti-HER2 treatment, and their concerns regarding potential increased cancer risk with less treatment. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 25, 2024 Category: Cancer & Oncology Source Type: research

Disentangling the relationships of body mass index and circulating sex hormone concentrations in mammographic density using Mendelian randomization
ConclusionOur findings support a positive causal association between BMI and mammographic non-dense area and an inverse association between BMI and dense area. Evidence was weaker and inconsistent for a causal effect of circulating sex hormone concentrations on mammographic density phenotypes. Based on our findings, associations between circulating sex hormone concentrations and mammographic density phenotypes are weak at best. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 24, 2024 Category: Cancer & Oncology Source Type: research

Impact of HER2 status on clinicopathological characteristics and pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
ConclusionsIn our cohort, HER2-low TNBC patients exhibits specific clinical characteristics and response features to NAC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 24, 2024 Category: Cancer & Oncology Source Type: research

Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane
ConclusionTo the best of our knowledge, we present here for the first time a comprehensive and direct head-to-head, intra-patient-cross-over comparison of the aromatase inhibitor letrozole and the aromatase inactivator exemestane concerning their ability to suppress serum estrogen levels in vivo. All in all, our results clearly demonstrate that letrozole therapy results in a more profound suppression of serum E1 and E2 levels compared to exemestane. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 23, 2024 Category: Cancer & Oncology Source Type: research

Racial disparities in outcomes of patients with stage I-III triple-negative breast cancer after adjuvant chemotherapy: a post-hoc analysis of the E5103 randomized trial
ConclusionThis clinical trial population of similarly treated TNBC patients showed no racial differences in breast cancer outcomes. Disease extent, rather than race, was associated with disease events. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 23, 2024 Category: Cancer & Oncology Source Type: research

Randomized trials of estrogen-alone and breast cancer incidence: a meta-analysis
ConclusionThe totality of randomized clinical trial evidence supports a conclusion that estrogen-alone use significantly reduces breast cancer incidence. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 23, 2024 Category: Cancer & Oncology Source Type: research

Ethnic disparities in breast cancer patterns in Brazil: examining findings from population-based registries
ConclusionThis study underscores the need for targeted policies to address disparities in access to early detection and proper treatment, particularly for Black women in underprivileged regions, aiming to improve the survival rates of Brazilian women grappling with BC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 21, 2024 Category: Cancer & Oncology Source Type: research

Evaluation of markers of immunity in different metastatic immune microenvironments suggests more suppression within breast to liver metastases in breast cancer
ConclusionsLvMs are less likely to express PD-L1+ tumor cells but more likely to harbor high TMB as compared to BrTs. Unlike AxMs, LvMs represent a more immunosuppressed TME and demonstrate lower gene expression associated with adaptive immunity compared to BrTs. These findings suggest biopsy site be considered when interpreting results that influence ICI use for treatment and further investigation of immune composition and biomarkers expression by metastatic site. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 20, 2024 Category: Cancer & Oncology Source Type: research

Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival —a propensity score cohort study
ConclusionPerforming SLNB before NACT results in more ALND and has no benefit for patient survival. These findings support discontinuing the practice of SLNB before NACT in patients with cN0 breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 18, 2024 Category: Cancer & Oncology Source Type: research

Tolerability and effectiveness of palbociclib in older women with metastatic breast cancer
ConclusionAlthough grade 3 –4 toxicity and dose reductions occurred frequently, most were expected and managed by dose reductions, showing that palbociclib is generally well tolerated and thus represents a valuable treatment option in the older population. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 16, 2024 Category: Cancer & Oncology Source Type: research

Is postmastectomy radiotherapy necessary for breast cancer patients with clinically node-positive downstaging to ypN0 after neoadjuvant chemotherapy?
ConclusionIn the context of comprehensive treatments, PMRT might be exempted in ypN0 breast cancer patients. Further large-scale, randomized controlled studies are required to investigate the significance of PMRT in this patient subset. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 15, 2024 Category: Cancer & Oncology Source Type: research

Uptake of screening and risk-reducing recommendations among women with hereditary breast and ovarian cancer syndrome due to pathogenic BRCA1/2 variants evaluated at a large urban comprehensive cancer center
ConclusionAn evaluation of follow up practice in a cohort of women with pathogenic variants inBRCA1/2 revealed high rates of reported completion of screening and surgical risk-reducing recommendations. Educational efforts should continue to reinforce the importance of follow-through with guideline recommended care among this high-risk group. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 12, 2024 Category: Cancer & Oncology Source Type: research

Retraction Note: Declining melatonin levels and MT1 receptor expression in aging rats is associated with enhanced mammary tumor growth and decreased sensitivity to melatonin
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 12, 2024 Category: Cancer & Oncology Source Type: research